Statins: Is It Really Time to Reassess Benefits and Risks?
- 10 May 2012
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 366 (19), 1752-1755
- https://doi.org/10.1056/nejmp1203020
Abstract
No drug provides health benefits without some degree of risk, and risk–benefit assessments require ongoing review as new data become available. This is certainly the case for the use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors — statins — and the risk of new-onset diabetes.Keywords
This publication has 6 references indexed in Scilit:
- Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin TherapyJAMA, 2011
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-AnalysisDiabetes Care, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Statins and diabetes – Authors' replyThe Lancet, 2008
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysisThe Lancet, 2008